Login to Your Account

With Doubts About its Efficacy, FDA Panel Nixes NicOx Drug

By Donna Young

Thursday, May 13, 2010
SILVER SPRING, Md. - An FDA panel Wednesday in a 16-to-1 vote, with one abstention, rejected NicOx SA's naproxcinod, a cyclooxygenase-inhibiting nitric oxide-donating compound, as a treatment to relieve the signs and symptoms of osteoarthritis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription